[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
September 2009

The Misperception That Clinical Trial Data Reflect Long-term Drug SafetyLessons Learned From Efalizumab's Withdrawal

Author Affiliations
 

MICHAELBIGBYMD

 

OLIVIERCHOSIDOWMD, PhDROSAMARIACORONADSc, MDROBERT P.DELLAVALLEMD, PhD, MSPHURBÀ GONZÁLEZMD, PhDCATALIN M.POPESCUMD, PhDABRAR A.QURESHIMD, MPHHYWELWILLIAMSMSc, PhD, FRCP

Arch Dermatol. 2009;145(9):1037-1039. doi:10.1001/archdermatol.2009.188

Commentary on: Press Release: European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab).

The European Medicines Agency

http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/2085709en.pdf

The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Raptiva (efalizumab), from Serono. The EMEA's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Raptiva no longer outweigh its risks, because of safety concerns, including the occurrence of progressive multifocal leukoencephalopathy (PML) in patients taking the medicine.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×